Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

SMi are delighted to welcome the expertise from a senior panel of big biotech's and pharma organisations, as well as regulatory bodies, at the inaugural Cell & Gene Therapy 2018 conference, taking ...